A Phase 1b / Randomized Phase 2a Trial of Indoximod in Combination With Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Trial Profile

A Phase 1b / Randomized Phase 2a Trial of Indoximod in Combination With Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Indoximod (Primary) ; Cytarabine; Idarubicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors NewLink Genetics Corporation
  • Most Recent Events

    • 02 Nov 2017 According to a NewLink Genetics Corporation media release, first patient has been dosed with the novel salt formulation of indoximod.
    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
    • 18 May 2017 According to a NewLink Genetics media release, initial results from the Phase 1b portion of this trial will be presented at the 22nd European Hematology Association (EHA) Annual Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top